CASSIE ROBINSON: Open Payments
NPI 1972823359 · CORINTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$470 in 23 payments from 8 companies in 2025. Trend: 2023 $687 · 2024 $518 · 2025 $470
Food & beverage: $470
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $148 |
| Astellas Pharma US Inc | 3 | $88 |
| Novo Nordisk Inc | 5 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Radius Health, Inc. | 1 | $30 |
| ABBVIE INC. | 2 | $30 |
| Abbott Laboratories | 1 | $22 |
Products named: Veozah, AIRSUPRA, BREZTRI, Wegovy, CAPLYTA, Qelbree, Tymlos, UBRELVY.
Industry payments across MS — which companies pay providers there.
